RUNX2 and neoplasm: Consistent with these findings, we demonstrated that CBFB silencing significantly reduced tumor burden; incidence of bone metastasis; and levels of CXCR4, OPN, Runx2, and IL-6 proteins and increased the survival rate in MDA-MB-436-injected tumor xenograft mouse models compared with their control counterparts (Figure 5).